Synonym
ML390; ML-390 ML 390.
IUPAC/Chemical Name
(R)-N-(3-oxo-3-((1,2,3,4-tetrahydronaphthalen-1-yl)amino)propyl)-4-(trifluoromethoxy)benzamide
InChi Key
SGNRHEDBLPGDDC-GOSISDBHSA-N
InChi Code
InChI=1S/C21H21F3N2O3/c22-21(23,24)29-16-10-8-15(9-11-16)20(28)25-13-12-19(27)26-18-7-3-5-14-4-1-2-6-17(14)18/h1-2,4,6,8-11,18H,3,5,7,12-13H2,(H,25,28)(H,26,27)/t18-/m1/s1
SMILES Code
O=C(NCCC(N[C@@H]1CCCC2=C1C=CC=C2)=O)C3=CC([H])=C(OC(F)(F)F)C=C3
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor.
In vitro activity:
This study found that ML390, a dihydroorotate dehydrogenase inhibitor, has potential anti-EV71 activity. ML390 dose-dependently inhibited EV71 replication with IC50 and selectivity index values of 0.06601 μM and 156.5, respectively.
Reference: Antiviral Res. 2023 Jan;209:105498. https://pubmed.ncbi.nlm.nih.gov/36563943/
In vivo activity:
ML390 exerts its potent differentiation effect on multiple leukemia models, though its mechanism of action is currently unknown. ML390 will be tested in mice harboring a HoxA9-driven acute myeloid leukemia to assess its differentiation effect as well as its effect on leukemic progression and overall survival.
Reference: Probe Reports from the NIH Molecular Libraries Program [Internet]. 2013 Dec 15 [updated 2015 Feb 11]. https://pubmed.ncbi.nlm.nih.gov/25834907/
|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
12.0 |
29.53 |
|
| DMSO |
42.7 |
104.99 |
|
| DMSO:PBS (pH 7.2) (1:2) |
0.3 |
0.74 |
|
| Ethanol |
31.5 |
77.51 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
406.41
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Yang Q, Wu C, Zhu G, Ren F, Lin B, Huang R, Hu X, Zhao D, Peng K, Wu Y, Wang Q, Huang C, Zhang D. ML390 inhibits enterovirus 71 replication by targeting de novo pyrimidine biosynthesis pathway. Antiviral Res. 2023 Jan;209:105498. doi: 10.1016/j.antiviral.2022.105498. Epub 2022 Dec 20. PMID: 36563943.
2. Sykes DB, Haynes MK, Waller A, Garcia M, Ursu O, Gouveia KE, Sklar L, Lewis TA, Dandapani S, Munoz B, Scadden DT, Palmer M, Schreiber SL. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. 2013 Dec 15 [updated 2015 Feb 11]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. PMID: 25834907.
In vitro protocol:
1. Yang Q, Wu C, Zhu G, Ren F, Lin B, Huang R, Hu X, Zhao D, Peng K, Wu Y, Wang Q, Huang C, Zhang D. ML390 inhibits enterovirus 71 replication by targeting de novo pyrimidine biosynthesis pathway. Antiviral Res. 2023 Jan;209:105498. doi: 10.1016/j.antiviral.2022.105498. Epub 2022 Dec 20. PMID: 36563943.
In vivo protocol:
1. Yang Q, Wu C, Zhu G, Ren F, Lin B, Huang R, Hu X, Zhao D, Peng K, Wu Y, Wang Q, Huang C, Zhang D. ML390 inhibits enterovirus 71 replication by targeting de novo pyrimidine biosynthesis pathway. Antiviral Res. 2023 Jan;209:105498. doi: 10.1016/j.antiviral.2022.105498. Epub 2022 Dec 20. PMID: 36563943.
2. Sykes DB, Haynes MK, Waller A, Garcia M, Ursu O, Gouveia KE, Sklar L, Lewis TA, Dandapani S, Munoz B, Scadden DT, Palmer M, Schreiber SL. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. 2013 Dec 15 [updated 2015 Feb 11]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010–. PMID: 25834907.
1. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. Timothy A. Lewis, David B. Sykes, Jason M. Law, Benito Muñoz, Joane K. Rustiguel, Maria Cristina Nonato, David T. Scadden, and Stuart L. Schreiber. Publication Date (Web): September 28, 2016 (Letter). DOI: 10.1021/acsmedchemlett.6b00316
2: Sykes DB, Haynes MK, Waller A, Garcia M, Ursu O, Gouveia KE, Sklar L, Lewis TA, Dandapani S, Munoz B, Scadden DT, Palmer M, Schreiber SL. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. 2013. Dec 15 [updated 2015 Feb 11]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK280053/PubMed PMID: 25834907.
